证券代码：300765 证券简称：新诺威 公告编号：2025-038 石药创新制药股份有限公司 2025 年第一季度报告披露提示性公告 董事会 2025 年 4 月 24 日 1 2025 年 4 月 23 日，石药创新制药股份有限公司（以下简称"公司"）分别 召开第六届董事会第二十三次会议、第六届监事会第十八次会议，审议通过了《关 于公司<2025 年第一季度报告>的议案》。公司《2025 年第一季度报告》于 2025 年 4 月 24 日 在 中 国 证 监 会 指 定 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露，敬请投资者注意查阅。 特此公告。 石药创新制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-037 石药创新制药股份有限公司 1、审议并通过《关于公司<2025 年第一季度报告>的议案》 经审议，监事会认为：《2025 年第一季度报告》的内容符合法律、行政法 规、中国证券监督管理委员会和深圳证券交易所的相关规定，报告内容真实、 准确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日刊载于中国证监会指定创业板信息披露网站巨潮资 讯网（www.cninfo.com.cn）上的相关公告。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 三、备查文件 第六届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 石药创新制药股份有限公司（以下简称"公司"或"上市公司"）第六届监 事会第十八次会议（以下简称"本次会议"）于 2025 年 4 月 23 日在公司会议室 以现场方式召开，会议通知于 2025 年 4 月 16 日以专人送出、电话通知、电子 邮件等方式送达全体监事。 会议由公司监事会主席张继勇先生主持。本次会议应出席 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-036 石药创新制药股份有限公司 第六届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 石药创新制药股份有限公司（以下简称"公司"或"上市公司"）第六届董 事会第二十三次会议（以下简称"本次会议"）于 2025 年 4 月 23 日在公司会议 室以现场加通讯表决相结合的方式召开，会议通知于 2025 年 4 月 16 日以专人送 出、电话通知、电子邮件等方式送达全体董事。 会议由公司董事长姚兵先生主持，公司监事与高级管理人员列席了本次会议。 本次会议应出席董事人数 9 人，实际出席董事人数 9 人。出席董事资格、人数以 及召集、召开程序等均符合《中华人民共和国公司法》等法律法规和《石药创新 制药股份有限公司章程》的规定，本次会议合法有效。 经审议，董事会认为：《2025 年第一季度报告》的内容符合法律、行政法规、 中国证券监督管理委员会和深圳证券交易所的相关规定，报告内容真实、准确、 完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详 ...

■■■10■■■■■■■■■■■■ ■■■■■■■■■■■■ 96632.59■■■■■■■■■■■ 77.49%■■■■■■■ 521.61■■■ | ■■ | ■■■■(■■) | ■■■■■■(%) | ■■■■(■■) | | --- | --- | --- | --- | | ■■■■■■■■■■■■■ | 87863.94 | 70.46 | 229.47 | | ■■■■■■■■■■ | 1595.42 | 1.28 | -72.12 | | ■■■■■■■■A | 1220.00 | 0.98 | ■■ | | ■■■■■■■■■■■■ | 1158.72 | 0.93 | ■■ | | ■■■■■601066■■■■■■■■■ | 1024.94 | 0.82 | -103.15 | | ■■■■■■ETF | 951.86 | 0.76 | -74.98 | | ■■■■■■■■■■■■■■-■■■■■■■■■■ | 790.00 | 0.63 | ■■ | | ■■■■■■■■■■■A | 719.04 | 0.58 | ■■ | | ■■■■■■■002173■■■A | 682.06 ...

Financial Performance - The company's revenue for Q1 2025 was ¥471,967,670.63, representing a decrease of 9.94% compared to ¥524,066,868.93 in the same period last year[5]. - The net profit attributable to shareholders for Q1 2025 was a loss of ¥26,901,607.29, a decline of 134.03% from a profit of ¥79,061,260.62 in Q1 2024[5]. - Total operating revenue for the current period was ¥471,967,670.63, a decrease of 9.9% compared to ¥524,066,868.93 in the previous period[22]. - The company reported a net profit of -142,361,032.21 yuan for the current period, compared to a net profit of 29,961,530.26 yuan in the previous period, indicating a significant decline[23]. - Operating profit for the current period was -126,574,064.46 yuan, while the previous period showed an operating profit of 56,155,547.90 yuan, reflecting a substantial decrease[23]. - The total comprehensive income for the current period was -142,313,442.07 yuan, compared to 29,589,098.69 yuan in the previous period[23]. - Basic and diluted earnings per share for the current period were both -0.0192 yuan, down from 0.0676 yuan in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥86,799,597.52, a 91.10% reduction compared to a net outflow of ¥975,365,408.34 in the previous year[12]. - Cash and cash equivalents at the end of the period reached ¥1,298,752,857.02, up 48.9% from ¥872,081,872.91 at the beginning of the period[19]. - The company reported cash and cash equivalents at the end of the period amounting to 1,298,752,857.02 yuan, a decrease from 2,686,302,001.07 yuan at the end of the previous period[26]. - The company generated cash inflow from investment activities amounting to 472,270,137.70 yuan, with a net cash flow from investment activities of 361,108,752.50 yuan[26]. - The company recorded a total operating cash inflow of 443,386,291.36 yuan, down from 576,280,891.81 yuan in the previous period[25]. - The company received 163,000,000.00 yuan from financing activities, resulting in a net cash flow from financing activities of 163,000,000.00 yuan[26]. Assets and Liabilities - The total assets at the end of Q1 2025 were ¥6,092,264,108.12, reflecting a 1.16% increase from ¥6,022,115,755.32 at the end of the previous year[5]. - Total assets increased to ¥6,092,264,108.12, compared to ¥6,022,115,755.32 at the beginning of the period, reflecting a growth of 1.2%[20]. - Total liabilities rose to ¥1,734,625,266.13, an increase of 13.7% from ¥1,526,185,458.97 in the previous period[20]. - The company's total equity decreased to ¥4,357,638,841.99 from ¥4,495,930,296.35, a decline of 3.1%[21]. - The company’s total equity attributable to shareholders decreased by 0.66% to ¥3,705,741,472.18 from ¥3,730,544,275.59 at the end of the previous year[5]. Research and Development - Research and development expenses surged by 117.68% to ¥240,479,825.00 in Q1 2025, up from ¥110,476,228.75 in Q1 2024, due to multiple products being in clinical development[11]. - Research and development expenses surged to ¥240,479,825.00, representing a significant increase from ¥110,476,228.75 in the previous period[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,564[14]. - The largest shareholder, Shijiazhuang Yiling Pharmaceutical Co., Ltd., holds 73.77% of shares, totaling 1,036,159,894 shares[14]. - The company has 157,520,510 restricted shares held by Shijiazhuang Yiling Pharmaceutical Co., Ltd., which are subject to a 36-month transfer restriction[16]. - The total number of shares held by the top 10 unrestricted shareholders is 878,639,384 shares[14]. - The company has not disclosed any changes in the top 10 shareholders due to margin trading activities[15]. - The company has not reported any changes in the number of preferred shareholders or their holdings[15]. - The company’s stock structure includes various institutional investors, with the top 10 shareholders holding a significant portion of the shares[14]. - The company’s financial disclosures indicate a commitment to transparency regarding shareholder relationships and potential risks associated with stock transfers[17]. Acquisition Plans - The company plans to acquire 100% equity of Shijiazhuang Baike Biopharmaceutical Co., Ltd. through a combination of cash and stock issuance, with the transaction currently under review by the Shenzhen Stock Exchange[17]. - The company will continue to provide updates on the acquisition process as it progresses through regulatory reviews[17].

新诺威（300765）公告，2025年第一季度营收为4.72亿元，同比下降9.94%；净亏损2690.16万元，去年 同期净利润7906.13万元。 ...

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed A fund, which has shown significant growth in its net value and returns over various time frames [1] - As of April 21, 2025, the latest net value of Zhongyin Innovation Medical Mixed A is 1.6127 yuan, reflecting a growth of 2.27% [1] - The fund's one-month return is 14.21%, ranking 9th out of 4672 similar funds; the three-month return is 36.72%, ranking 18th out of 4599; and the year-to-date return is 34.02%, ranking 36th out of 4590 [1] Group 2 - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with significant positions in companies such as Heng Rui Pharmaceutical (9.81%), Innovent Biologics (8.55%), and others [1] - The fund was established on November 13, 2019, and as of December 31, 2024, it has a total scale of 2.02 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry since 2022 [2]

Core Viewpoint - The recent performance of the Zhongyin Innovation Medical Mixed A fund shows a decline in net value but strong returns over various time frames, indicating potential resilience in the healthcare investment sector [1]. Fund Performance Summary - The latest net value of Zhongyin Innovation Medical Mixed A is 1.5786 yuan, down by 2.81% - The fund's one-month return is 13.30%, ranking 7 out of 4623 in its category - The three-month return stands at 38.74%, ranking 14 out of 4566 - Year-to-date return is 31.19%, ranking 24 out of 4559 [1]. Holdings Summary - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with the following key positions: - Heng Rui Pharmaceutical: 9.81% - Xinda Bio: 8.55% - Huaneng Pharmaceutical: 8.41% - Kangfang Biotech: 8.35% - Kangnuo Ya-B: 8.32% - Kelun Botai: 7.87% - BeiGene-U: 6.24% - Rongchang Bio: 5.96% - Hansoh Pharmaceutical: 3.98% - Xin Nuo Wei: 3.11% [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and extensive experience in the investment sector, having previously worked at Taikang Asset Management and Zhonggeng Fund Management - Zheng joined Zhongyin Fund Management in 2022 and has managed multiple funds since then, including the Zhongyin Innovation Medical Mixed Fund [2].